How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/moxifloxacin-ethambutol-isoniazid-pyrazinamide-rifampicin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

Moxifloxacin, Ethambutol, Isoniazid, Pyrazinamide & Rifampicin — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Moxifloxacin, Ethambutol, Isoniazid, Pyrazinamide & Rifampicin (Moxifloxacin, Ethambutol, Isoniazid, Pyrazinamide & Rifampicin) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Anti-tuberculosis agent combination. Area: Infectious Disease.

phase 3 Anti-tuberculosis agent combination Multiple: DNA gyrase (moxifloxacin), RNA polymerase (rifampicin), mycolic acid synthesis (isoniazid, pyrazinamide), arabinosyl transferase (ethambutol) Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

Moxifloxacin, Ethambutol, Isoniazid, Pyrazinamide & Rifampicin (Moxifloxacin, Ethambutol, Isoniazid, Pyrazinamide & Rifampicin) — Global Alliance for TB Drug Development. This is a fixed-dose combination of five anti-tuberculosis agents that work through multiple mechanisms to inhibit bacterial cell wall synthesis, protein synthesis, and DNA replication in Mycobacterium tuberculosis.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Moxifloxacin, Ethambutol, Isoniazid, Pyrazinamide & Rifampicin TARGET	Moxifloxacin, Ethambutol, Isoniazid, Pyrazinamide & Rifampicin	Global Alliance for TB Drug Development	phase 3	Anti-tuberculosis agent combination	Multiple: DNA gyrase (moxifloxacin), RNA polymerase (rifampicin), mycolic acid synthesis (isoniazid, pyrazinamide), arabinosyl transferase (ethambutol)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Anti-tuberculosis agent combination class)

Global Alliance for TB Drug Development · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Moxifloxacin, Ethambutol, Isoniazid, Pyrazinamide & Rifampicin — Competitive Intelligence Brief. https://druglandscape.com/ci/moxifloxacin-ethambutol-isoniazid-pyrazinamide-rifampicin. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab